EIC Innovator’s Summit 2018

Published on 13/09/2018

ENYO Pharma was present at the EIC Innovators’ Summit in Berlin on September, 10th-11th 2018, organized by the European Innovation Council. We had the pleasure to make presentations at several workshops during this summit. The workshops allowed participants to be creative and to strengthen their knowledge thanks to several experience sharings of our team members. On this occasion, it was a great opportunity for ENYO Pharma to have fruitful meetings and conversations, to exchange experiences and explore business opportunities.

Read next in 'Latest news'

• La Phase 2
• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)